Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): follow-up at 43 months Rischin, D., Khushalani, N. I., Schmults, C. D., Guminski, A., Chang, A. S., Lewis, K. D., Lim, A. M., Hernandez-Aya, L., Hughes, B. M., Schadendorf, D., Hauschild, A., Stankevich, E., Booth, J., Yoo, S., Okoye, E., Lowy, I., Fury, M. G., Migden, M. R. WILEY. 2021: 166

View details for Web of Science ID 000717281500265